BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells

Neoplasia (United States)

Volumn 20, Issue 7, 2018, Pages 697-709

  Hollingsworth, Julia ^a,b   Lau, Angela ^a,b   Tone, Alicia ^b,c   Kollara, Alexandra ^a,b   Allen, Lisa ^b   Colgan, Terence J ^a,b,d   Dube, Valerie ^b,e,g   Rosen, Barry ^b,c,h   Murphy, K Joan ^b,c,g   Greenblatt, Ellen M ^a,b   Feigenberg, Tomer ^b,c,g   Virtanen, Carl ^f   Brown, Theodore J ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (United States)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

^f Princess Margaret Genomics Centre   (United States)

^g CREDIT VALLEY HOSPITAL   (Canada)

^h WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSCRIPTOME;

ADULT; ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FALLOPIAN TUBE EPITHELIUM; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY FOLLICLE FLUID; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL CULTURE; CYTOLOGY; FALLOPIAN TUBE; FEMALE; GENE REGULATORY NETWORK; METABOLISM; MIDDLE AGED; MUTATION; PHYLOGENY; TUMOR SUPPRESSOR GENE;

ADULT; BIOMARKERS; CELLS, CULTURED; EPITHELIAL CELLS; FALLOPIAN TUBES; FEMALE; FOLLICULAR FLUID; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MUTATION; NF-KAPPA B; PHYLOGENY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 85053449907     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2018.05.005     Document Type: Article

References (57)

1. Crum, CP, Drapkin, R, Miron, A, Ince, TA, Muto, M, Kindelberger, DW, Lee, Y, The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19 (2007), 3–9.
2. Chen, S, Parmigiani, G, Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25 (2007), 1329–1333.
3. King, MC, Marks, JH, Mandell, JB, Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003), 643–646.
4. Mavaddat, N, Peock, S, Frost, D, Ellis, S, Platte, R, Fineberg, E, Evans, DG, Izatt, L, Eeles, RA, Adlard, J, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105 (2013), 812–822.
5. Boyd, J, Sonoda, Y, Federici, MG, Bogomolniy, F, Rhei, E, Maresco, DL, Saigo, PE, Almadrones, LA, Barakat, RR, Brown, CL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283 (2000), 2260–2265.
6. Havrilesky, LJ, Moorman, PG, Lowery, WJ, Gierisch, JM, Coeytaux, RR, Urrutia, RP, Dinan, M, McBroom, AJ, Hasselblad, V, Sanders, GD, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 122 (2013), 139–147.
7. Tung, KH, Wilkens, LR, AH, Wu, McDuffie, K, Nomura, AM, Kolonel, LN, Terada, KY, Goodman, MT, Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 161 (2005), 321–329.
8. McGuire, V, Felberg, A, Mills, M, Ostrow, KL, DiCioccio, R, John, EM, West, DW, Whittemore, AS, Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160 (2004), 613–618.
9. McLaughlin, JR, Risch, HA, Lubinski, J, Moller, P, Ghadirian, P, Lynch, H, Karlan, B, Fishman, D, Rosen, B, Neuhausen, SL, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8 (2007), 26–34.
10. Buscher, U, Chen, FC, Kentenich, H, Schmiady, H, Cytokines in the follicular fluid of stimulated and non-stimulated human ovaries; is ovulation a suppressed inflammatory reaction?. Hum Reprod 14 (1999), 162–166.
11. Fleming, JS, Beaugie, CR, Haviv, I, Chenevix-Trench, G, Tan, OL, Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247 (2006), 4–21.
12. Tone, AA, Begley, H, Sharma, M, Murphy, J, Rosen, B, Brown, TJ, Shaw, PA, Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 14 (2008), 4067–4078.
13. Tone, AA, Virtanen, C, Shaw, P, Brown, TJ, Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis. Clin Cancer Res 18 (2012), 4334–4344.
14. Fotheringham, S, Levanon, K, Drapkin, R, Ex vivo culture of primary human fallopian tube epithelial cells. J Vis Exp, 51, 2011, 2728, 10.3791/2728.
15. Lee, YL, Lee, KF, JS, Xu, Wang, YL, Tsao, SW, Yeung, WS, Establishment and characterization of an immortalized human oviductal cell line. Mol Reprod Dev 59 (2001), 400–409.
16. Lau, A, Kollara, A, St John, E, Tone, AA, Virtanen, C, Greenblatt, EM, King, WA, Brown, TJ, Altered expression of inflammation-associated genes in oviductal cells following follicular fluid exposure: implications for ovarian carcinogenesis. Exp Biol Med (Maywood) 239 (2014), 24–32.
17. Bahar-Shany, K, Brand, H, Sapoznik, S, Jacob-Hirsch, J, Yung, Y, Korach, J, Perri, T, Cohen, Y, Hourvitz, A, Levanon, K, Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol 132 (2014), 322–327.
18. Johnson, WE, Li, C, Rabinovic, A, Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8 (2007), 118–127.
19. Shannon, P, Markiel, A, Ozier, O, Baliga, NS, Wang, JT, Ramage, D, Amin, N, Schwikowski, B, Ideker, T, Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13 (2003), 2498–2504.
20. Loeb, KR, Haas, AL, The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267 (1992), 7806–7813.
21. H, Xu, Xian, J, Vire, E, McKinney, S, Wei, V, Wong, J, Tong, R, Kouzarides, T, Caldas, C, Aparicio, S, Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells. J Pathol 234 (2014), 386–397.
22. Ezell, SA, Polytarchou, C, Hatziapostolou, M, Guo, A, Sanidas, I, Bihani, T, Comb, MJ, Sourvinos, G, Tsichlis, PN, The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proc Natl Acad Sci U S A 109 (2012), E613–E621.
23. Hoesel, B, Schmid, JA, The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12:86 (2013), 1–15.
24. Sau, A, Lau, R, Cabrita, MA, Nolan, E, Crooks, PA, Visvader, JE, Pratt, MA, Persistent Activation of NF-kappaB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. Cell Stem Cell 19 (2016), 52–65.
25. Benezra, M, Chevallier, N, Morrison, DJ, MacLachlan, TK, El-Deiry, WS, Licht, JD, BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem 278 (2003), 26333–26341.
26. LN Burga, H Hu, Juvekar, A, Tung, NM, Troyan, SL, Hofstatter, EW, Wulf, GM, Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res, 13, 2011, R30.
27. Li, D, Bi, FF, Cao, JM, Cao, C, Li, CY, Yang, Q, Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer. J Exp Clin Cancer Res, 32, 2013, 102, 10.1186/1756-9966-32-102 6 pp.
28. De, S, Dermawan, JK, Stark, GR, EGF receptor uses SOS1 to drive constitutive activation of NFkappaB in cancer cells. Proc Natl Acad Sci U S A 111 (2014), 11721–11726.
29. Shostak, K, Zhang, X, Hubert, P, Goktuna, SI, Jiang, Z, Klevernic, I, Hildebrand, J, Roncarati, P, Hennuy, B, Ladang, A, et al. NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nat Commun, 5, 2014, 5232, 10.1038/ncomms6232 19 pp.
30. Nottingham, LK, Yan, CH, Yang, X, Si, H, Coupar, J, Bian, Y, TF Cheng, C, Allen, P, Arun, D Gius, et al. Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 33 (2014), 1135–1147.
31. Biswas, DK, Cruz, AP, Gansberger, E, Pardee, AB, Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97 (2000), 8542–8547.
32. Le Page, C, Koumakpayi, IH, Lessard, L, Mes-Masson, AM, Saad, F, EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 65 (2005), 130–140.
33. Jiang, T, Grabiner, B, Zhu, Y, Jiang, C, Li, H, You, Y, Lang, J, Hung, MC, Lin, X, CARMA3 is crucial for EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res 71 (2011), 2183–2192.
34. Lassus, H, Sihto, H, Leminen, A, Joensuu, H, Isola, J, Nupponen, NN, Butzow, R, Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) 84 (2006), 671–681.
35. Jazaeri, AA, Yee, CJ, Sotiriou, C, Brantley, KR, Boyd, J, Liu, ET, Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94 (2002), 990–1000.
36. Chi, LM, Lee, CW, Chang, KP, Hao, SP, HM Lee, Y, Liang, C, Hsueh, CJ Yu, Lee, IN, Chang, YJ, et al. Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics 8 (2009), 1453–1474.
37. Andersen, JB, Aaboe, M, Borden, EC, Goloubeva, OG, Hassel, BA, Orntoft, TF, Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 94 (2006), 1465–1471.
38. Kiessling, A, Hogrefe, C, Erb, S, Bobach, C, Fuessel, S, Wessjohann, L, Seliger, B, Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene 28 (2009), 2606–2620.
39. Tsai, YC, Pestka, S, Wang, LH, Runnels, LW, Wan, S, Lyu, YL, Liu, LF, Interferon-beta signaling contributes to Ras transformation. PLoS One, 6, 2011, e24291.
40. Bogunovic, D, Boisson-Dupuis, S, Casanova, JL, ISG15: leading a double life as a secreted molecule. Exp Mol Med, 45, 2013, e18.
41. Burks, J, Reed, RE, Desai, SD, Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective. Oncotarget 6 (2015), 7221–7231.
42. Dastur, A, Beaudenon, S, Kelley, M, Krug, RM, Huibregtse, JM, Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J Biol Chem 281 (2006), 4334–4338.
43. Desai, SD, Reed, RE, Burks, J, Wood, LM, Pullikuth, AK, Haas, AL, Liu, LF, Breslin, JW, Meiners, S, Sankar, S, ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med 237 (2012), 38–49.
44. Fan, JB, Miyauchi-Ishida, S, Arimoto, K, Liu, D, Yan, M, Liu, CW, Gyorffy, B, Zhang, DE, Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proc Natl Acad Sci U S A 112 (2015), 14313–14318.
45. Darb-Esfahani, S, Sinn, BV, Rudl, M, Sehouli, J, Braicu, I, Dietel, M, Denkert, C, Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-kappaB pathway. Int J Gynecol Pathol 33 (2014), 16–22.
46. Einav, U, Tabach, Y, Getz, G, Yitzhaky, A, Ozbek, U, Amariglio, N, Izraeli, S, Rechavi, G, Domany, E, Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 24 (2005), 6367–6375.
47. Zhao, C, Denison, C, Huibregtse, JM, Gygi, S, Krug, RM, Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A 102 (2005), 10200–10205.
48. Chairatvit, K, Wongnoppavich, A, Choonate, S, Up-regulation of interferon-stimulated gene15 and its conjugates by tumor necrosis factor-alpha via type I interferon-dependent and -independent pathways. Mol Cell Biochem 368 (2012), 195–201.
49. Minakawa, M, Sone, T, Takeuchi, T, Yokosawa, H, Regulation of the nuclear factor (NF)-kappaB pathway by ISGylation. Biol Pharm Bull 31 (2008), 2223–2227.
50. Takeuchi, T, Kobayashi, T, Tamura, S, Yokosawa, H, Negative regulation of protein phosphatase 2Cbeta by ISG15 conjugation. FEBS Lett 580 (2006), 4521–4526.
51. Malakhov, MP, Kim, KI, Malakhova, OA, Jacobs, BS, Borden, EC, Zhang, DE, High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 278 (2003), 16608–16613.
52. Liu, LQ, Ilaria, R Jr., Kingsley, PD, Iwama, A, van Etten, RA, Palis, J, DE Zhang. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 19 (1999), 3029–3038.
53. Mustachio, LM, Lu, Y, Kawakami, M, Roszik, J, Freemantle, SJ, Liu, X, Dmitrovsky, E, Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target. Cancer Res 78 (2018), 587–592.
54. Honke, N, Shaabani, N, Zhang, DE, Hardt, C, Lang, KS, Multiple functions of USP18. Cell Death Dis, 7, 2016, e2444.
55. He, YH, Zhang, HN, Zhang, GP, Hou, N, Xiao, Q, Huang, Y, Wu, JH, Luo, MS, Zhang, GS, Yi, Q, et al. A physiological concentration of glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts: roles of extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB. Clin Exp Pharmacol Physiol 38 (2011), 739–746.
56. Lei, B, Mace, B, Dawson, HN, Warner, DS, Laskowitz, DT, James, ML, Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. PLoS One, 9, 2014, e103969.
57. Xing, D, Oparil, S, Yu, H, Gong, K, Feng, W, Black, J, Chen, YF, Nozell, S, Estrogen modulates NFkappaB signaling by enhancing IkappaBalpha levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-beta. PLoS One, 7, 2012, e36890.